Search research articles
Contact Us
Filters
Showing results (91-100 of 261) with videos related to
Page
of 27
Sort By:
Journal of Patient-Reported Outcomes
|
July 1, 2025
NASH-CHECK patient-reported outcome instrument: evaluation of content and face validity for patients with metabolic dysfunction-associated steatohepatitis and compensated cirrhosis
Lynda C Doward, Matthew Breckons, Maria-Magdalena Balp, et al.
Journal of Hepatology
|
April 28, 2026
Erratum to 'Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis' [J Hepatol 83 (2025) 239-257]
Andressa de Zawadzki, Diana J Leeming, Arun J Sanyal, et al.
Journal of Hepatology
|
October 10, 2022
Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons
Juan M Pericàs, Frank Tacke, Quentin M Anstee, et al.
Cell Cycle (Georgetown, Tex.)
|
March 15, 2014
Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease
Aloysious Aravinthan, George Mells, Michael Allison, et al.
Journal of Clinical Gastroenterology
|
October 17, 2022
Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis
Ira M Jacobson, Vincent Wai-Sun Wong, Laurent Castera, et al.
Alimentary Pharmacology & Therapeutics
|
September 23, 2025
Exploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients With MASH
Louise Maymann Nitze, Vlad Ratziu, Arun J Sanyal, et al.
Plos One
|
September 11, 2020
Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis
Jenny Lee, Yasaman Vali, Jérôme Boursier, et al.
Psychiatric Genetics
|
March 28, 2017
Genetic variation in GABRβ1 and the risk for developing alcohol dependence
William A McCabe, Michael J Way, Kush Ruparelia, et al.
Clinical Epigenetics
|
April 11, 2015
Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease
Müjdat Zeybel, Timothy Hardy, Stuart M Robinson, et al.
Contemporary Clinical Trials
|
November 16, 2019
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
Marcos Pedrosa, Star Seyedkazemi, Sven Francque, et al.
Page
of 27
Search research articles
Search
Showing results (91-100 of 261) with videos related to
Sort By:
Page
of 27
Journal of Patient-Reported Outcomes
|
July 1, 2025
NASH-CHECK patient-reported outcome instrument: evaluation of content and face validity for patients with metabolic dysfunction-associated steatohepatitis and compensated cirrhosis
Lynda C Doward, Matthew Breckons, Maria-Magdalena Balp, et al.
Journal of Hepatology
|
April 28, 2026
Erratum to 'Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis' [J Hepatol 83 (2025) 239-257]
Andressa de Zawadzki, Diana J Leeming, Arun J Sanyal, et al.
Journal of Hepatology
|
October 10, 2022
Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons
Juan M Pericàs, Frank Tacke, Quentin M Anstee, et al.
Cell Cycle (Georgetown, Tex.)
|
March 15, 2014
Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease
Aloysious Aravinthan, George Mells, Michael Allison, et al.
Journal of Clinical Gastroenterology
|
October 17, 2022
Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis
Ira M Jacobson, Vincent Wai-Sun Wong, Laurent Castera, et al.
Alimentary Pharmacology & Therapeutics
|
September 23, 2025
Exploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients With MASH
Louise Maymann Nitze, Vlad Ratziu, Arun J Sanyal, et al.
Plos One
|
September 11, 2020
Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis
Jenny Lee, Yasaman Vali, Jérôme Boursier, et al.
Psychiatric Genetics
|
March 28, 2017
Genetic variation in GABRβ1 and the risk for developing alcohol dependence
William A McCabe, Michael J Way, Kush Ruparelia, et al.
Clinical Epigenetics
|
April 11, 2015
Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease
Müjdat Zeybel, Timothy Hardy, Stuart M Robinson, et al.
Contemporary Clinical Trials
|
November 16, 2019
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
Marcos Pedrosa, Star Seyedkazemi, Sven Francque, et al.
Page
of 27